Kreitman R J, Pastan I
Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Semin Cancer Biol. 1995 Oct;6(5):297-306. doi: 10.1006/scbi.1995.0038.
Malignant cells of hematopoietic origin often express a variety of different growth factor receptors and antigens on their surface, at levels much higher than normal cells. These malignant cells can be selectively targeted with Pseudomonas exotoxin (PE) derivatives directed by interleukins 2, 4 and 6, and by Fv fragments of monoclonal antibodies to interleukin 2 receptor (IL2R) subunits, CD22 and other antigens present on these cells. Anti-Tac(Fv)-PE38, a single-chain recombinant immunotoxin which targets cells bearing the IL2Ra, is furthest along in preclinical development and is being prepared for clinical testing in patients with IL2Ra-positive leukemia, lymphoma and Hodgkin's disease.
造血系统来源的恶性细胞通常在其表面表达多种不同的生长因子受体和抗原，其水平远高于正常细胞。这些恶性细胞可以被白细胞介素2、4和6导向的铜绿假单胞菌外毒素（PE）衍生物，以及针对白细胞介素2受体（IL2R）亚基、CD22和这些细胞上存在的其他抗原的单克隆抗体的Fv片段选择性靶向。抗Tac（Fv）-PE38是一种靶向携带IL2Ra的细胞的单链重组免疫毒素，在临床前开发中进展最远，正在准备用于IL2Ra阳性白血病、淋巴瘤和霍奇金病患者的临床试验。
